Novo Nordisk A/S ADR(NVO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low47.02
Day High47.65
Open:47.10
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Zacks Investment Research
LLY or PFE: Which Drugmaker Offers the Stronger Growth Story?
LLY or PFE: Which Drugmaker Offers the Stronger Growth Story?
Tipranks
Analysts Conflicted on These Healthcare Names: Phreesia (PHR) and Novo Nordisk (NVO)
Motley Fool
2 Underrated Weight Loss Stocks to Buy and Hold
Motley Fool
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
Motley Fool
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Motley Fool
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?
Motley Fool
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
MarketBeat
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
MarketBeat.com
Tipranks
Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)
Tipranks
After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?
Tipranks
Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters
Zacks Investment Research
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
Tipranks
Novo Nordisk’s Iraq Haemophilia Study Adds Real‑World Support for Turoctocog Alfa
Zacks Investment Research
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
Tipranks
Berenberg Bank Remains a Buy on Novo Nordisk (0QIU)
Motley Fool
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?
Tipranks
Novo Nordisk Expands 2026 Share Buyback, Holding 0.8% of Capital in Treasury Shares
Motley Fool
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Zacks Investment Research
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?

Profile

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.